27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
ApoE4 did not moderate the EF and falls relationship (p ≥ 0.05). 5 key findings →
Design: cross-sectional Participants: 486 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patients with DLB had significantly greater rates of hospitalization and ED visits compared to patients with AD (Incidence Rate Ratio (IRR): 1.46, 95% CI 1.24, 1.73, IRR: 1.46, 95% CI 1.29, 1.77, respectively) and controls (IRR: 1.77, 95% CI 1.46, 2.14, IRR: 2.21, 95% CI 1.82, 2.69, respectively) and ED visits compared to those with VD (IRR: 1.24, 95% CI 1.03, 1.50). 5 key findings →
Participants: 175 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
(n = 14) included NH administrators and other leaders, palliative care providers, telehealth representatives, dementia advocates, a care partner, and a PLWD. 5 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study cohort for the analysis of inpatient palliative care comprised 43,896 patients, while the cohort for the analysis of outpatient palliative care included a total of 37,430 patients. 5 key findings →
Participants: 37,430 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Unmet PC needs were highly prevalent (78.2%). 4 key findings →
Participants: 359 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of the 258 surveyed doctors, 74 (28.7%) practiced ACP. 5 key findings →
Design: cross-sectional Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants with Lewy body dementia described losses associated with communication, continence, and energy leading to a progressive loss of independence. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We interviewed 30 participants (9 PWD, 21 carepartners). 4 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
DNS conditions, particularly dementia, were associated with longer survival among non-oncologic HBPC patients. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Various approaches to advance care planning are in use and generally acceptable also for persons with dementia and their care partners. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 197 participants were included in the study. 5 key findings →
Participants: 197 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
WMH burden positively correlated to Neurofilament-Light (NfL) and pTau181. 5 key findings →
Design: cross-sectional Participants: 583 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The final analysis included 459,924 participants. 5 key findings →
Participants: 459,924 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Lecanemab, an anti-amyloid monoclonal antibody, has been approved for treatment of early Alzheimer's disease. 2 key findings →
Participants: 137 Evidence: low
Full summary, score breakdown and related studies → Original source
Food choices profoundly impact population health and the environment. 2 key findings →
Participants: 290 Evidence: low
Full summary, score breakdown and related studies → Original source
Food choices profoundly impact population health and the environment. 2 key findings →
Participants: 290 Evidence: low
Full summary, score breakdown and related studies → Original source
This Viewpoint discusses the Wasteful and Inappropriate Service Reduction (WISeR) model, a new payment model announced by the Centers for Medicare & Medicaid Services Innovation Center to broaden prior authorization in traditional Medicare. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This cross-sectional study examines trends in coverage of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide, and prior authorization requirements among Medicare Part D beneficiaries. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Eleven studies involving 1,536 PLWH were included. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Global CL quantification of Aβ PET scans is highly concordant with visual interpretation. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Through analytical validation, this assay demonstrated robust performance across multiple lots, operators, and instruments and could be used as a tool for diagnosing AD. 5 key findings →
Participants: 1,091 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
With the introduction of the new causal amyloid targeting therapies, the role of biomarker-assisted diagnosis of Alzheimer disease (AD) has received a further boost. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Key results included a 35% slowing of decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) and a 36% slowing on the Clinical Dementia Rating-Sum of Boxes (CDR-SB). 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (DS) stands out as the most prevalent genetic contributor to intellectual disability, marked by the presence of an extra copy of chromosome 21 (HSA21). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Apolipoprotein E ε4 (APOE ε4) bring the higher risk of Alzheimer' Disease (AD). 4 key findings →
Participants: 1,610 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →